Brokers Issue Forecasts for GeoVax Labs Q1 Earnings

GeoVax Labs Inc. (NASDAQ:GOVX) – Noble Financial issued their Q1 2027 earnings per share estimates for GeoVax Labs in a report released on Wednesday, July 29th. Noble Financial analyst R. Leboyer expects that the company will post earnings of ($0.63) per share for the quarter. The consensus estimate for GeoVax Labs’ current full-year earnings is ($8.69) per share. Noble Financial also issued estimates for GeoVax Labs’ Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.67) EPS and Q4 2027 earnings at ($0.68) EPS.

Several other brokerages have also recently commented on GOVX. Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Stock Down 3.9%

Shares of GOVX opened at $0.70 on Thursday. GeoVax Labs has a 52-week low of $0.64 and a 52-week high of $20.62. The stock has a market cap of $2.42 million, a PE ratio of -0.04 and a beta of 3.68. The firm’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.77.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($2.16) by $1.19.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new position in shares of GeoVax Labs in the 4th quarter valued at approximately $99,000. HRT Financial LP bought a new position in GeoVax Labs during the 4th quarter worth approximately $31,000. Renaissance Technologies LLC acquired a new stake in shares of GeoVax Labs during the 4th quarter valued at approximately $104,000. Finally, Armistice Capital LLC acquired a new position in GeoVax Labs in the third quarter worth $253,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.